Skip to main content
ZheJiang Tailin Bioengineering Co.,Ltd logo

ZheJiang Tailin Bioengineering Co.,Ltd — Investor Relations & Filings

Ticker · 300813 ISIN · CNE100003S89 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,000 across all filing types
Latest filing 2023-04-26 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 300813

About ZheJiang Tailin Bioengineering Co.,Ltd

https://www.tailingood.com

ZheJiang Tailin Bioengineering Co.,Ltd. specializes in the research, development, and manufacturing of high-tech equipment for life sciences and pharmaceutical engineering. The company provides integrated solutions for microbial control, sterility testing, and aseptic processing. Its core product portfolio includes sterility test canisters and pumps, microbial limit testing systems, and hydrogen peroxide vapor (VHP) decontamination units. Tailin also develops advanced isolator technology for containment and aseptic applications, alongside analytical instruments such as Total Organic Carbon (TOC) analyzers and filter integrity testers. These products are designed to meet international regulatory standards, including GMP, USP, and EP. The company serves sectors such as biopharmaceuticals, medical devices, and laboratory research, focusing on product safety and quality through specialized engineering and microbial detection technologies.

Recent filings

Filing Released Lang Actions
2023年一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '浙江泰林生物技术股份有限公司2023 年第一季度报告' which translates to 'Zhejiang Tailin Biotechnology Co., Ltd. 2023 First Quarter Report'. It contains detailed financial data including balance sheets, income statements, cash flow statements, and shareholder information for the first quarter of 2023. The document explicitly states it is a quarterly report and includes comprehensive financial statements and analysis for the quarter. It also mentions that the report is unaudited. The length of the document (11,397 characters) and the detailed financial content confirm it is a full interim/quarterly report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2023
2023-04-26 Chinese
2022年限制性股票激励计划预留授予激励对象名单（授予日）
Share Issue/Capital Change Classification · 95% confidence The document is a list of recipients for a restricted stock incentive plan, detailing the allocation of shares to middle management and key personnel. It includes specific numbers of shares granted and percentages relative to total company stock. The document is short (970 characters) and focuses on share incentive allocation rather than financial results, management changes, or regulatory filings. It is not an announcement of a report, nor a full financial or management report. The content aligns with a Share Issue/Capital Change announcement, as it relates to stock grants under an incentive plan, which is a capital change event.
2023-04-26 Chinese
第三届监事会第十一次会议决议公告
Regulatory Filings Classification · 95% confidence The document is an announcement of the resolutions passed at the 11th meeting of the third Supervisory Board of Zhejiang Tailin Biotechnology Co., Ltd. It includes the approval of the 2023 first quarter report and adjustments to the 2022 restricted stock incentive plan. The document does not contain the full quarterly report or detailed financial statements but refers readers to the official website for the full 2023 first quarter report. The document is relatively short (2053 characters) and serves as a formal announcement of meeting decisions and approvals rather than the report itself. Therefore, it fits best as a Regulatory Filing (RNS) since it is a formal disclosure of supervisory board resolutions and approvals without the full report content.
2023-04-26 Chinese
上海锦天城（杭州）律师事务所关于浙江泰林生物技术股份有限公司调整2022年限制性股票激励计划限制性股票数量及授予价格、作废2022年限制性股票激励计划部分已授予尚未归属的限制性股票、向激励对象授予预留限制性股票的法律意见书
Capital/Financing Update Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding adjustments to a 2022 restricted stock incentive plan of Zhejiang Tailin Biotechnology Co., Ltd. It discusses the adjustment of the number and grant price of restricted stocks, cancellation of some granted but unvested restricted stocks, and the granting of reserved restricted stocks to incentive recipients. The document references relevant laws and regulations, board and shareholder approvals, and compliance with regulatory requirements. It is a legal advisory document related to stock incentive plans and does not contain financial statements, earnings data, or general regulatory announcements. It is not a report of financial results, audit, or management discussion, nor is it a simple announcement or certification. The content is focused on legal opinions about stock incentive plan adjustments, which aligns with filings related to capital or financing updates, specifically about stock-based compensation plans and equity incentives. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2023-04-26 Chinese
上海市锦天城律师事务所关于浙江泰林生物技术股份有限公司2022年年度股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the 2022 Annual General Meeting (AGM) of Zhejiang Tailin Biotechnology Co., Ltd. It details the legality and validity of the AGM procedures, attendees, voting results, and resolutions passed. The document includes specific voting results on various agenda items such as the 2022 annual report, board reports, profit distribution, audit firm appointment, and changes to the company charter. The document is not the annual report itself but a legal opinion on the AGM and its resolutions. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially reports the voting outcomes of the AGM. The document length is about 4990 characters, which is sufficient for a detailed voting results announcement rather than a brief notice or a full annual report. Therefore, the correct classification is DVA with high confidence.
2023-04-26 Chinese
关于向激励对象授予预留限制性股票的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the granting of reserved restricted stocks under a 2022 restricted stock incentive plan by Zhejiang Tailin Biotechnology Co., Ltd. It includes specifics about the stock grant date, number of shares, grant price, eligibility, approval procedures, performance conditions, and legal and financial advisor opinions. The content focuses on the company's stock incentive plan and the granting of shares to employees and management, which is a capital/financing related update rather than a full financial report or earnings release. It is not a report publication announcement since it contains substantive details and is not merely announcing the availability of a report. It is not a management change announcement or a voting result declaration. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2023-04-26 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.